NA
VIR icon

NewEdge Advisors’s Vir Biotechnology VIR Stock Holding History

NewEdge Advisors’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-20
Closed -$114 – 4383
2025
Q3 		$114 Hold
20
– – ﹤0.01% 4028
2025
Q2 		$101 Hold
20
– – ﹤0.01% 3904
2025
Q1 		$130 Hold
20
– – ﹤0.01% 3820
2024
Q4 		$147 Hold
20
– – ﹤0.01% 3760
2024
Q3 		$150 Buy
+20
New +$174 ﹤0.01% 3699
2023
Q3 		– Sell
-909
Closed -$22.3K – 3665
2023
Q2 		$22.3K Buy
909
+200
+28% +$5.02K ﹤0.01% 2354
2023
Q1 		$16.5K Hold
709
– – ﹤0.01% 2401
2022
Q4 		$18 Buy
+709
New +$17.4K ﹤0.01% 3620

Other funds holding VIR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GP
GSK plc London $602M AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

NewEdge Advisors's VIR Position: Q4 2025 in Review

NewEdge Advisors sold out of Vir Biotechnology (VIR) in Q4 2025, closing a stake of 20 shares — an estimated $114 sold.

NewEdge Advisors first reported a position in VIR in Q4 2022 and held it in 8 quarters. The position peaked at $22.3K in Q2 2023. 218 funds tracked by Wall St. Rank hold VIR as of Q4 2025.

  • NewEdge Advisors reported no remaining Vir Biotechnology position as of Q4 2025 after selling out during the quarter.
  • NewEdge Advisors sold 20 Vir Biotechnology shares in Q4 2025, an estimated $114.
  • NewEdge Advisors first reported a position in Vir Biotechnology in Q4 2022 and held it in 8 quarters.
  • NewEdge Advisors's Vir Biotechnology position peaked at $22.3K in Q2 2023.
  • 218 funds tracked by Wall St. Rank held Vir Biotechnology as of Q4 2025.

Based on NewEdge Advisors's 13F filing for Q4 2025, filed 18 Feb 2026.